Henry Schein Inc. (HSIC) has been acknowledged as a long-term investment. The healthcare giant has seen a rise in stock price and is participating in upcoming investor conferences. Despite currency challenges, their Q1 2025 earnings highlights show strategic growth. They have announced a strategic investment from KKR and subsequent board changes, while providing preliminary unaudited financial results and financial guidance for 2025. Other factors include solid Q4 2024 results, weaker-than-expected sales in Q1, and underperformance in the NASDAQ. They have completed the acquisition of Acentus, a supplier of homecare medical products, and lead a $250 million private placement. The company has received recognition for net-zero science-based targets and was named in FORTUNE Magazine’s ‘Change the World’ list. They also weathered a price target adjustment and have an adjusted severance plan in place. Despite a mixed bag in the Q1 2025 earnings, the CEO remains confident in their business fundamentals. The earnings revealed a miss on quarterly revenue estimates due to weak demand for dental products.
Henry Schein HSIC News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Thu, 29 May 2025 18:05:30 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -1
